CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 19 enrolled
Drug / intervention
SXC-2023 +1 moredrug
Likely dose
SXC-2023 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06343532
NCT06343532Phase 1Completed
CompareCT.gov

Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral SXC-2023

National Institute on Drug Abuse (NIDA)·interventional·Posted Apr 2, 2024·Updated Apr 24, 2026

In Brief

A Phase 1 clinical trial evaluating SXC-2023 and SXC-2023 Placebo for Cocaine Use Disorder. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Use Disorder
CountriesUnited States
CollaboratorsPromentis Pharmaceuticals, Inc., Altasciences Company Inc., Technical Resources International, Inc.

Timeline

Phase 1CompletedFinished
20252026
First PostedApr 2, 2024
Enrollment StartOct 8, 2024
Primary CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.3 years ago

Interventions

SXC-2023drug

200 mg capsules

SXC-2023 Placebodrug

200 mg capsules